8-K: NextCure Merges with Avere Therapeutics, Secures $320M Financing

NextCure, Inc. and Avere Therapeutics, Inc. have entered into a definitive merger agreement, combining Avere's oral IL-23 program with NextCure's public infrastructure, supported by a $320 million private placement.

Summary

• NextCure, Inc. (NXTC) has entered into a definitive merger agreement with Avere Therapeutics, Inc., a privately-held biotechnology company.
• The transaction is an all-stock deal, combining Avere's lead program, AVR-001, an oral IL-23 receptor antagonist, with NextCure's public market infrastructure.
• A concurrent private placement of $320 million, led by Fairmount and Hansoh Pharmaceutical Group, will fund the combined company.
• The combined company will operate as Avere Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol AVRX.
• The merger is anticipated to close in the second half of 2026, subject to customary closing conditions, including stockholder approvals and regulatory filings.
• The financing is expected to fund the combined company through key clinical milestones for AVR-001, including Phase 2b readouts in psoriasis and ulcerative colitis.
• NextCure stockholders will receive a contingent value right (CVR) entitling them to 90% of net proceeds from future monetization of NextCure's pipeline assets over two years post-closing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, driven by a significant financing round and a strategic merger aimed at advancing a promising clinical asset, although risks associated with clinical development and integration remain.

Positives

• Merger with Avere Therapeutics to advance AVR-001, an oral IL-23 program.
• Secured $320 million in private placement financing from a strong investor syndicate.
• The financing is expected to provide runway through key clinical milestones for AVR-001.
• Avere's experienced management team, with a track record of successful biotech ventures, will lead the combined company.
• AVR-001 has demonstrated promising Phase 1b data in psoriasis, supporting once-weekly oral dosing.
• The combined company will have immediate access to public markets via Nasdaq listing.
• NextCure stockholders will receive CVRs, providing potential upside from future monetization of NextCure's pipeline assets.

Negatives

• The exchange ratio for the merger is subject to adjustment based on NextCure's net cash position prior to closing.
• Options for NextCure common stock with an exercise price above the Parent Closing Price will be cancelled for no consideration.
• The merger is subject to stockholder approval from both companies, which may not be obtained.
• The transaction is complex, involving multiple agreements and regulatory approvals, which could lead to delays or failure to close.
• The CVRs are contingent on future monetization of NextCure's pipeline assets, with no assurance of payment.
• NextCure is undergoing a restructuring and workforce reduction plan, incurring approximately $1.9 million in charges.

Risks

• Failure to satisfy closing conditions, including stockholder approval or regulatory approvals.
• Risks associated with the clinical development of AVR-001, including potential delays or unfavorable results.
• The combined company's ability to manage expenses and unanticipated costs.
• Competition in the IL-23 market and the risk that competitors may develop superior therapies.
• Dependence on the in-licensed Hansoh program and the terms of that license agreement.
• Potential for clinical data generated by Hansoh outside the U.S. to not be replicated or accepted by the FDA.
• Risks related to intellectual property protection and potential third-party infringement claims.

Future Outlook

The combined company expects to be well-capitalized through the $320 million private placement, which is anticipated to fund operations through the readout of a global Phase 2b trial in psoriasis, the initiation of a Phase 3 trial in psoriasis, and the initiation of a Phase 2b trial in ulcerative colitis. The company aims to advance AVR-001 as a convenient, once-weekly oral therapy competitive with existing oral IL-23 inhibitors.

Management Comments

• "The combination of the strong clinical data from Hansohs Phase 1b psoriasis study, the capital raised through this financing from a world-class investor syndicate, and immediate access to the public markets positions us to be highly competitive in the emerging oral IL-23 market," said Andrew Cheng, MD, PhD, CEO of Avere.
• "We have a clear line of sight to potentially value-generating clinical data and the resources to execute our plans. We are focused on rapidly delivering a once-weekly oral IL-23 therapy that combines best-in-class convenience with efficacy competitive with other emerging oral IL-23 therapies."
• "Since our founding, NextCure has been committed to advancing innovative therapies designed to improve outcomes for patients. I am incredibly proud of the dedication, talent, and perseverance of the NextCure team and the important contributions they have made in pursuit of our mission," said Michael Richman, President and CEO of NextCure.
• "We are pleased to announce this transaction with Avere, which represents a compelling opportunity for NextCures stockholders to participate in the development of once-weekly AVR-001 and its significant therapeutic and commercial potential."
• "NextCures Board of Directors and management team are in full support of this transaction, and we believe Averes strong balance sheet and experienced management team are well-positioned to successfully execute on the development plans for AVR-001."

Industry Context

StockSavvy.ai notes that the merger and financing position Avere Therapeutics to compete in the growing market for oral IL-23 therapies for inflammatory diseases. The focus on a once-weekly oral administration for AVR-001 addresses a key patient convenience factor, potentially differentiating it from existing treatments.

Management Changes

Stakeholder Impact

• NextCure stockholders are expected to own approximately 1.21% of the combined company, subject to adjustments, and will receive CVRs for potential future monetization of NextCure's pipeline assets.
• Avere stockholders, including investors in the private placement, are expected to own approximately 98.79% of the combined company.
• Employees of NextCure may be impacted by the workforce reduction plan, with approximately $1.9 million in charges expected.
• The merger and financing are subject to various closing conditions, including stockholder approvals, which could impact the timing and completion of the transaction for all stakeholders.

Next Steps

• File Form S-4 registration statement with the SEC.
• Obtain stockholder approvals for the merger from both NextCure and Avere.
• Obtain Nasdaq approval for the listing of the combined company's shares.
• Complete the merger transaction, expected in the second half of 2026.
• Initiate Phase 2b study for AVR-001 in psoriasis in early 2027.
• Initiate Phase 2b study for AVR-001 in ulcerative colitis.

Key Dates

Recommendation

The merger and financing provide a clear path for Avere's lead asset, AVR-001, with strong clinical data and substantial funding. However, the significant dilution for NextCure stockholders (expected ~1.21% ownership) and the inherent risks in clinical development and regulatory approval warrant a cautious 'hold' stance until further clinical data and regulatory milestones are achieved.

Keywords

Merger Agreement, Avere Therapeutics, NextCure, AVR-001, IL-23, Biotechnology, Private Placement, Form 8-K